Edgewise Therapeutics, Inc.
NASDAQ:EWTX
25.28 (USD) • At close March 13, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 1.732 | 0.538 | 0.272 | 0.185 | 0.123 |
| Gross Profit
| 0 | -1.732 | -0.538 | -0.272 | -0.185 | -0.123 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 126.966 | 89.354 | 16.612 | 32.189 | 14.983 | 8.624 |
| General & Administrative Expenses
| 31.866 | 23.452 | 5.467 | 11.026 | 2.209 | 1.3 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 31.866 | 23.452 | 5.467 | 11.026 | 2.209 | 1.3 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 158.832 | 114.357 | 22.079 | 43.215 | 17.192 | 9.924 |
| Operating Income
| -158.832 | -114.357 | -22.079 | -43.215 | -17.192 | -9.924 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 25.019 | 14.194 | 4.018 | 0.402 | 0.069 | 0.219 |
| Income Before Tax
| -133.813 | -100.163 | -19.415 | -42.813 | -17.123 | -9.705 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 0 | -4.018 | -0.674 | -0.069 | -0.219 |
| Net Income
| -133.813 | -100.163 | -15.397 | -42.139 | -17.054 | -9.486 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -1.45 | -1.57 | -0.29 | -0.85 | -0.35 | -0.19 |
| EPS Diluted
| -1.45 | -1.57 | -0.29 | -0.85 | -0.35 | -0.19 |
| EBITDA
| -158.832 | -112.806 | -67.102 | -42.943 | -17.007 | -9.801 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |